## Figure 2.
Cost-Benefit Model for Interactions between MAR inducers and Antibiotics.a. The combined growth cost of two drugs (S and A) is assumed to be Bliss independent,
as long as the effective concentration of one drug is reduced by the presence of the
second drug. Thus, the combined cost of both drugs is approximately equal to the sum
of effective growth costs, f and g, for each individual drug. The reduction of each
drug's growth cost depends on the concentration of the other drug, which in turn dictates
the growth benefit provided. b. mar promoter activity, defined as the steady state time-averaged Fluorescence/OD times
relative growth rate, increases as a function of salicylate concentration. Error bars
are +/− one estimated standard deviation. Inset: mar fluorescence concentration (YFP
fluorescence/optical density) time series for concentrations of salicylate ranging
from 0 mM (purple) to 6 mM (blue). Data points are means over two replicates. Promoter
activity is estimated by averaging fluorescence concentration in the steady state
and multiplying by relative growth rate.
Wood and Cluzel |